The gross margin expansion to 59.3% suggests strong pricing power in premium IOLs and consumables, but the operating margin collapse to 0.4% from 15.5% in the prior quarter indicates a deliberate surge in R&D and SG&A spending, as noted in the income statement analysis. This divergence implies that while the core product economics remain healthy, the company is investing heavily in future growth, likely in pipeline development and commercial expansion, which may compress near-term profitability. Investors should monitor whether this spending translates into sustained revenue acceleration or if it reflects a structural cost escalation that erodes the historical operating leverage.

The consistently low ROIC, despite strong gross margins, suggests that the heavy investment in manufacturing, R&D, and the Aerie acquisition has not yet generated outsized returns. The stability of ROIC around 1% implies that the company is maintaining its capital efficiency rather than compounding returns, which may reflect the early stages of its post-spin investment cycle. As the installed base of surgical systems grows and premium lens penetration increases, ROIC could improve, but the current data suggests a gradual, not exponential, trajectory.

The lengthening of the cash conversion cycle, primarily due to a rise in days inventory outstanding to 197 days, suggests that Alcon is building inventory, possibly in anticipation of new product launches or to mitigate supply chain risks. DSO has remained relatively stable around 66-67 days, while DPO has increased modestly to 75 days, indicating some supplier leverage. This trend may indicate a deliberate strategy to ensure product availability, but it also ties up cash and could pressure liquidity if demand softens.

The reported debt/equity of 0.25 appears understated relative to prior analysis indicating several billion in long-term debt, but the D/EBITDA spike to 19.34 in 2026Q2 is driven by the collapse in EBITDA due to the operating margin decline, not a change in debt levels. Interest coverage fell to 0.13 in 2026Q2, reflecting the same earnings dip, but this is likely a temporary artifact of the strategic spending surge. Investors should monitor whether EBITDA recovers in subsequent quarters; if not, the leverage metrics could signal a more persistent strain on debt service capacity.

The current ratio remains above 2.0, suggesting that Alcon can cover short-term obligations comfortably, but the downward trend from 2.77 to 2.09 over six quarters indicates a gradual erosion of the liquidity cushion, partly due to aggressive capital returns and inventory buildup. The quick ratio of 1.30 in 2026Q2, down from 1.77 in 2024Q4, shows that inventory is becoming a larger component of current assets, which could be a concern if demand weakens. The company's ability to maintain this buffer under stress appears adequate, but the trend warrants monitoring.